ADHD and Anxiety: Clinical Significance and Treatment Implications (Q47448521)

16 January 2018

title

ADHD and Anxiety: Clinical Significance and Treatment Implications (English)

1 reference

16 January 2018

author name string

Frederick W Reimherr

1 reference

16 January 2018

Barrie K Marchant

1 reference

16 January 2018

Thomas E Gift

1 reference

16 January 2018

Tammy A Steans

1 reference

16 January 2018

language of work or name

English

0 references

publication date

20 November 2017

1 reference

16 January 2018

Current Psychiatry Reports

published in

1 reference

16 January 2018

volume

1 reference

16 January 2018

issue

1 reference

16 January 2018

page(s)

109

1 reference

16 January 2018

Internalizing and externalizing behavior in adult ADHD.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Emotional dysregulation in adult ADHD and response to atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Adult attention deficit hyperactivity disorder in an anxiety disorders population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Temperament and attention deficit hyperactivity disorder: the development of a multiple pathway model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Six-year follow-up study of combined type ADHD from childhood to young adulthood: Predictors of functional impairment and comorbid symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Anxiety in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

The Efficacy of 2 Different Dosages of Methylphenidate in Treating Adults with Attention-Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Psychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Validation of the adult ADHD investigator symptom rating scale (AISRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: the role of comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Severity but not comorbidities predicts response to methylphenidate in adults with attention-deficit/hyperactivity disorder: results from a naturalistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

A possible effect of methylphenidate on state anxiety: A single dose, placebo controlled, crossover study in a control group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-017-0859-6

Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD

21 January 2018

1 reference

12 December 2020

Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms

1 reference

12 December 2020

Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.

1 reference

12 December 2020

Psychometric properties of the Self-Report Wender-Reimherr Adult Attention Deficit Disorder Scale

1 reference

12 December 2020

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial

1 reference

12 December 2020

A one year trial of methylphenidate in the treatment of ADHD

1 reference

12 December 2020

Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder

1 reference

12 December 2020

10.1007/S11920-017-0859-6

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018